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Thedevelopmentandoptimizationofhigh-throughputscreeningmethodshasidentiﬁedamultitudeofgeneticchangesassociated
withhumandisease.Theuseofimmunodeﬁcientandgeneticallyengineeredmousemodelsthatmimicthehumandiseasehasbeen
crucial in validating the importance of these genetic pathways in prostate cancer. These models provide a platform for ﬁnding
novel therapies to treat human patients aﬄicted with prostate cancer as well as those who have debilitating bone metastases. In
this paper, we focus on the historical development and phenotypic descriptions of mouse models used to study prostate cancer.
We also comment on how closely each model recapitulates human prostate cancer.
1.Introduction
The American Cancer Society estimates that approximately
218,000 men will be diagnosed with, and 32,000 men will
die of, prostate cancer in the United States in 2010 [1]. To
givethesenumberscontext,prostatecancer(PCa)isthemost
commonly diagnosed cancer in men and is responsible for
the second highest number of cancer-related deaths in men
in the United States. PCa represents 27.6% of new cancer
cases in men and 10.7% of cancer-related deaths in men [1].
An estimated 1 in 3 men will be diagnosed with PCa or a
precancerous prostatic lesion in their lifetime [2]. In Europe,
there are approximately 346,000 new PCa cases and 87,000
d e a t h sp e ry e a r[ 3].
Age is the main risk factor for prostate cancer; between
2002 and 2006, the median age at diagnosis was 68, and
the median age at death was 80 [4]. Approximately 95% of
men over the age of 70 present with prostatic hyperplasia
[5]. Though many men are aﬄicted with PCa, most will not
die of the disease. Surgery, radiation therapy, and androgen
deprivation therapy have increased survival rates. “Watchful
waiting” is also an option for patients (especially those
over the age of 75) who have more indolent disease and
who might not beneﬁt from intense treatment [4]. Upon
diagnosis(viabiopsyfollowingadigitalrectalexam(DRE)or
a prostate-speciﬁc antigen (PSA) screen) clinicians generally
base treatment on Gleason score [6] and tumor stage. The
ﬁve-year survival rate PCa patients after diagnosis at local
stages is 100%, but for metastatic disease, it is only 30.6%
[7].
PCa is largely dependent on androgens for growth
and proliferation; hence, androgen deprivation therapy
(chemical castration) is the standard of treatment, and it
generally causes prostate tumors to regress. However, most
PCa cases eventually recur after treatment. These more
lethal cases generally have a high Gleason score and can
be metastatic and/or refractory to androgen deprivation
therapy (castration resistant). Skeletal metastasis is the most
signiﬁcant cause of morbidity and mortality in PCa [8].
Skeletal metastases are found in approximately 90% of
patients who die of PCa [9]. This adds to the health burden
of these patients while they are still alive, due to painful
lesions that impair mobility and cause pathologic fractures,
spinal cord compression, and symptomatic hypercalcemia
[10]. The frequency of bone metastases in PCa indicates that
the microenvironment of the bone may promote the growth
of PCa cells. The proportion of active osteoblasts is usually
greaterthanthatofactiveosteoclastsinPCabonemetastases,
resulting in the net formation (rather than lysis) of bone
in a majority of these lesions [11]. However, osteolysis is
requiredformetastatictumorcellstoinvadethebonematrix.
Also, patients with bone metastases have a higher risk of2 Prostate Cancer
fracture, indicating that bone destruction is occurring. One
study suggests that there may be more bone lysis during
prostate tumor metastasis than originally thought and that
it might be more prevalent in PCa than other diseases [12].
While much work has been done in the area of prostate
tumor-bone crosstalk [13–15], there is still much to learn
in this area. Accordingly, there is an urgent need for new
treatments and better experimental models for the study of
PCa development, progression, and metastasis.
PCa is a heterogeneous disease in which malignant
cells arise from the epithelial layers of the prostate. These
layers comprise luminal secretory cells, basal cells, and rare
neuroendocrinecells.AdiagnosticfeatureofPCaisaluminal
phenotype and the loss of diﬀerentiated basal cells [16]. A
debateisongoingastowhichtypeofepithelialcellrepresents
the cell of origin for PCa: luminal stem cells [16], basal
stem cells [17], or both [18]. Given the heterogeneity of the
disease and the many genetic pathways that are involved,
there is likely a complex explanation [19]. An understanding
of where malignant cells arise from in the prostate may be
of vital importance for the development of more eﬀective
treatments [20]. Mouse models may provide valuable insight
into this challenging question.
Mouse modeling has made a signiﬁcant contribution to
the study of prostate development and disease. This paper
reviews the history and development of some of the most
common mouse models of PCa and discusses the genetic
alterations that were used to make the models, as well as the
clinical implications of each model. It is important to note
that the genetic backgrounds of the models are outside the
scope of this paper; this topic has been reviewed elsewhere
[21].
2. Nonmouse Models
Immortalized cell lines have been used extensively to study
variousaspectsofPCa,particularlyintermsofgeneticdereg-
ulation. In 2005, a two-part review was written examining
PCa cell lines in detail [22, 23]. Another article characterized
17celllinessoastosimplifytheselectionprocessforresearch
[24]. An issue with cell lines is that they are commonly
derivedfrommetastaticlesions,thereforeprecludinganalysis
of genetic alterations that transform normal prostate cells
to malignant cells. However, while care must be taken in
extrapolating from in vitro data to in vivo meaning, PCa cell
lines provide a model for identifying prospective gene targets
in a fast and eﬃcient manner, as well as for determining
molecular mechanisms. Primary cell cultures, taken directly
from tumor tissue, also provide a model for studying various
aspects of PCa [25]. The development of improved in vivo
modelsshouldallowresearcherstoextendtheinsightsgained
from the decades of cell culture work.
PCa occurs naturally in dogs and in some strains of rats
[26].ThedogmostcloselyresembleshumansintermsofPCa
characteristics [27]. PCa in the dog metastasizes to bone in
an osteoblastic manner in 24% of cases [28]. Canine PCa is
also age dependent. While dogs may seem an ideal model for
studyingPCa,therearelimitationstotheiruse.Theinstances
of PCa do not diminish in castrated dogs, indicating that
tumor growth is not androgen dependent [28]. There is also
a relatively long latency in dogs. The high cost, long gestation
period, and diﬃculty of genetic manipulation make the dog
an unrealistic experimental model.
Several strains of rats, including the Dunning, Copen-
hagen, and Wistar rats, have been well characterized, and
they develop a wide range of cancer phenotypes in the
prostate [29–31]. However, due to the rarity of tumors,
variability in phenotypes, long latency periods, and lack of
metastases, the realistic probability of using them as models
is low. Three articles have recently been published describing
diﬀerent methods of generating knockout rats [32–34]. This
indicates that the use of the rat as a genetically engineered
model could increase in the coming years [35].
3. ProstateCancer MouseModels
3.1. Pros and Cons of Mice in Translational Research. Nat-
urally occurring PCa is uncommon in the mouse; after a
two-year study by the National Toxicology Program of 612
mice, there were no spontaneous cases of carcinoma in
the prostate [36]. Therefore, a great deal of work has been
done to manipulate mice so that they develop PCa that
accurately recapitulates human disease. Mouse and human
prostate anatomy is dissimilar. The mouse prostate has a
lobular structure with four lobes—anterior (also known as
the coagulating gland), ventral, dorsal, and lateral (these
last two lobes are commonly referred to as the dorsolateral
lobe) [37]. Alternatively, the human prostate has one “lobe”
divided into three zones: central, transitional, and peripheral
(Figure 1). The majority of human PCa is found in the
peripheral zone, which comprises about 75% of the tissue in
the prostate. The mouse dorsolateral lobe has been described
as the most similar to the human peripheral zone [38], but
the consensus opinion of the Bar Harbor Pathology Panel is
that there is no direct relationship between any one mouse
lobe and any of the zones of the human prostate [36]. An
additionalconcernisthatthehistopathologyandtime-frame
of prostatic disease development can be diﬀerent in mice
[36]. Also, the lifespan of a mouse is 30–50 times shorter
than that of humans, and mice are about 3,000 times smaller
[39]. This means, for example, that pharmacokinetics during
drug studies tends to diﬀer between mice and humans due
to the size diﬀerence [40]. Cancer metastases in mice have
a propensity to originate from mesenchymal cells whereas
human metastases generally originate from epithelial cells,
especially in PCa [41]. Finally, it has proven diﬃcult to
induce bone metastases in mice, which is a problem because
this type of metastasis is common in human PCa patients
[13]. All of these factors provide challenges for mouse
researchers and must be considered when extrapolating
research conclusions from mice to humans.
Despite the several concerns, the mouse is still one of the
bestanimalsinwhichtomodelhumancancer.First,miceare
as susceptible to cancer as humans [39]. However, the type
of cancer that mice are aﬄicted with is not always reﬂective
of that in humans; mice tend to have more sarcomas andProstate Cancer 3
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Figure 1: Schematic illustration of the anatomy of the human prostate (a) and mouse prostate (b) (adapted from McNeal [42] and Cunha
et al. [43], resp.). Used with permission: Abate-Shen and Shen [2].
lymphomas and fewer carcinomas [44–46]. This may be due
to diﬀerences in relative telomere length and function [46].
Second, the mouse and human genomes are approximately
95%identical,andmicehavemanystructurallysimilargenes
and genomic alterations that have been implicated in cancer
[40, 47]. Third, mice are relatively easy to genetically modify,
especially with the Cre-loxP system (reviewed later in this
paper). Finally, because mice have a relatively short gestation
time andare small,they arereasonablyeasyandaﬀordableto
house and breed to generate large populations.
The goal of every mouse model is to accurately imitate
human disease so that molecular mechanisms can be found
andnewtherapiescanbetested.Anexampleofthesuccessful
use of a mouse model in translational cancer research
is the modeling of the BCR-ABL translocation and the
eﬃciency of the kinase inhibitor Gleevec to treat acute
myelogenous leukemia (AML) [48]. The ideal PCa mouse
model would exhibit hyperproliferation and hyperplasia
in prostate epithelial cells leading to prostatic intraepithe-
lial neoplasia (PIN), which is a noninvasive precursor to
PCa (Figure 2). The aﬀected prostate would then develop
noninvasive carcinoma in situ, commonly known as high-
grade PIN (HGPIN). The next stage would be locally
invasive adenocarcinoma, followed by metastatic disease
and/or castration resistance. Because human PCa most often
metastasizes to the skeleton and lymph nodes, these would
be the most ideal sites in the mouse. During the stages listed
thus far, the ideal model would display androgen-dependent
disease. It would be beneﬁcial for the ideal model to
eventually develop castration-resistant disease, comparable
to the human disease that is currently untreatable. The
histopathologic features and molecular pathways that are
changed in humans should also be changed in the mouse.
Finally,theresponseoftheidealmodeltotherapeuticswould
accurately reﬂect the response in humans. More ideas about
limitations and goals of modern mouse models can be found
in a review from 2008 [49].
3.2. Five Main Categories of Prostate Cancer Mouse Models.
Over the past few decades, numerous PCa mouse models
have been developed, studied, and characterized. We will
discuss some of the most relevant models in the ﬁeld within
ﬁve categories. The ﬁrst category comprises the xenograft
models, of which there are many kinds. The ﬁnal four
categories fall under the broad class of genetically engineered
mouse models (GEMMs). These include transgenic models
that use prostate-speciﬁc promoters to express the SV40 T
antigen, as well as those expressing other oncogenes. The
fourth and ﬁfth categories are traditional and conditional
knockout models.
3.2.1. Xenograft Models. A common in vivo PCa model is
the immunodeﬁcient mouse as a recipient of human tumor
tissue,celllines,orprimarycellcultures.Thesemiceareused
becauseoftheirinabilitytomountanimmunologicresponse
to foreign (i.e., human) tissue, allowing human tumors
to grow relatively unabated. These systems are responsible
for important insights into the mechanisms underlying
many human tumors, and they allow for propagation and
expansion of patient-speciﬁc material. Human samples can
be serially transplanted in parallel to numerous individual
mice so that the eﬃcacy of speciﬁc treatments can be
evaluated. This approach holds promise for identifying the
most eﬀective treatments for human patients [50]. These
models have also been used to determine stem cell-like
properties of cancer cells. The number of models using
a xenograft system is potentially endless because of the
multitude of genetic alterations and combinations (as well as
the wide range of human tumor tissue) that can be grafted
into immunodeﬁcient mice. Therefore, we will discuss the
most common immunodeﬁcient mice and their relative lack
of immunity and then discuss several examples of PCa-
speciﬁc models that were generated using these mice with
the caveat that there are numerous other xenograft models
described elsewhere.
Nude Mice. The ﬁrst xenotransplantation of human PCa
tissue, the androgen-responsive PC-82 tumor model, was
demonstrated in 1980 in athymic nude mice on a BALB/c
genetic background [51]. Nude mice are deﬁcient in T4 Prostate Cancer
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Figure 2: Stages of prostate cancer. The goal of genetically engineered mouse models is to accurately mimic all of these stages of human
disease in the mouse.
lymphocytes due to lack of a thymus, so they cannot mount
an immunologic response to foreign tissue. The rate of
successfulxenograftswasapproximately3%until1996,when
seven new xenograft models were described at a take rate
of 38% using the newer NMRI nude strain (developed at
the Naval Marine Research Institute) [52]. Since that time,
many diﬀerent models have been developed using athymic
nude mice [53]. An example is a model that demonstrated
the ability of a xenograft to metastasize to the lymph node
and axial skeleton [54]. In this model, cells from the C4-
2 PCa cell line (a castration-resistant subline of the LNCaP
cell line) were injected subcutaneously at diﬀerent sites, as
wellasorthotopicallyintothedorsolateralprostatelobe.Bear
in mind that orthotopic implantation has been considered a
more accurate representation of the original disease, due to
a more accurate representation of the microenvironment of
the growing tumor [55]. This model resembled human PCa
in that the metastases were found in the lymph node and
bone, the two most common sites of human PCa metastasis
[54].
SCID Mice. Severe combined immunodeﬁciency (SCID) is
a rare disease in which the aﬀected organism is unable
to mount an immune response due to loss of B and
T lymphocytes. Mice with an autosomal recessive SCID
mutation were characterized in 1983 [56]. SCID mice are
deﬁcient in mature B and T cells, due to a defect in genetic
recombination necessary for lymphoid development [57].
However, natural killer (NK) cells and myeloid cells appear
normal in SCID mice [57, 58] ,a n ds o m eS C I Dm i c ea r e
“leaky,” meaning that some B and T cells are still present.
Therefore, some SCID mice will reject foreign tissue [59].
SCID mice were used in a model in which the tyrosine
kinase HER2/neu was overexpressed in LNCaP cells (an
immortalized PCa cell line), which were subcutaneously
injected into the mice. The goal of this model was to
determine if HER2/neu could induce androgen-independent
growth of tumors. This was shown to be true and was
due to modulation of the androgen receptor (AR) signaling
pathway[60].AnothermodelistheSCID-hu(SCID-human)
in which human fetal bone is implanted subcutaneously
into the ﬂank of the mouse [61]. In this model, PCa cells
(which can be genetically modiﬁed to suit the experimental
hypothesis) are injected into the tail vein of the mouse, and
the ability of these cells to metastasize to the human bone is
measured and compared [61].
NOD-SCID Mice. To improve the immunodeﬁcient prop-
erties of the SCID model, SCID mice were crossed to
nonobese diabetic (NOD) mice, which are deﬁcient in
NK cells, circulating complement, and functional antigen-
presenting cells (APCs) [62, 63]. NOD-SCID mice were
able to accept foreign tissue at a higher success rate and
weremoreimmunodeﬁcientthanSCIDmice(Figure 3)[64].
However, there is evidence of remnant NK cell activity in
these mice [65]. Two years after the PCa SCID-hu model
wasdescribed[61],similarworkwasdoneintheNOD-SCID
model [66]. Human adult bone was implanted into the mice
subcutaneously, and PCa cells wereinjected into the tail vein.
Metastasis to the bone occurred at a higher rate in the NOD-
SCID mice (13/20 mice) relative to SCID mice (5/19 mice)
[61, 66].
NOG/NSG Mice. Another improvement of the immunode-
ﬁcient mouse occurred when NOD-SCID mice were crossed
to interleukin 2 receptor γ (IL2Rγ) null mice (also known
as X-SCID mice) which are completely lacking NK cells [67–
69]. This model is generally referred to as the NOG or NSG
model, and it is currently the most severely immunodeﬁcient
mouseavailable[70,71].Thesemicehaveacompleteabsence
of B, T, and NK cells, have a deﬁciency in cytokine signaling,
and show no phenotypic “leakiness” after a year of age.
NOG/NSG mice have a higher xenograft success rate than
NOD-SCID mice (13/13 compared to 8/13, when human
hematopoietic stem cells were injected) [71]. NOG mice
also survived longer than NOD-SCID mice (median of 89
weeks compared to 37 weeks [71]) making them a more
valuable model, especially for long-term studies. The use of
the NOG/NSG mouse over other immunodeﬁcient mice can
make a drastic diﬀerence in experimental results, as shown
in an article that reported diﬀering results after performing
limited dilution analysis in NOD-SCID and NOG/NSG
mice [72]. A recent article describes the eﬀectiveness of the
NOG/NSG mice over nude mice [73]. In this study, PCa
cells were injected subcutaneously into nude and NOG/NSG
mice. Palpable tumors grew in all of the mice, but after 6–
16 weeks, the tumors stopped growing and regressed in the
nude mice whereas the tumors in the NOG/NSG mice grew
atanacceleratedrateanddidnotregress[73].Thisillustrates
the utility of growing xenografts in NOG/NSG mice.
RAG Mice. RAG mice are deﬁcient in the recombination
activating gene (RAG). Two proteins, RAG1 and RAG2, are
synergistically responsible for activation of V(D)J recombi-
nation during T cell development [74, 75]. When either of
these proteins is inactivated, the mice are deﬁcient in both B
and T cells, similar to SCID mice [76, 77]. These mice also
have an inﬂammatory response and NK cell activity. A PCa-
speciﬁc model using these mice was reported in 2006, when
castration resistant TRAMP-C2 cells were subcutaneouslyProstate Cancer 5
injected into RAG1 null mice to ascertain eﬀectiveness of a
speciﬁc antitumor treatment [78].
Renal Grafts and Intrabone Injections. Renal grafting and
intrabone injections are two in vivo model systems that
merit further discussion. Renal grafting is the process of
recombining PCa cells with raturogenital sinus mesenchyme
(UGM) cells and then transplanting this recombinant tissue
beneath the kidney capsule in an immunodeﬁcient mouse
(historically nude or SCID) to assess growth and other
phenotypes [79]. The recombining of prostate cells and
UGM cells was ﬁrst described in 1978, the purpose being to
determine the importance of the mesenchyme for androgen
dependency [80]. This procedure is currently most com-
monly used to determine the ability of putative prostate
stem cells to generate prostatic tissue and ducts. This model
has been used to show that castration resistant Nkx3.1-
expressing cells (CARNs) are putative prostate luminal
epithelial stem cells [16]. Another study used this system
to show that a single Lin−Sca1+CD133+CD44+CD117+ cell
could regenerate substantial prostate ductal structures [81].
Another purpose for renal grafting is to determine the
physiological signiﬁcance of genes that cannot be studied via
whole body knockouts due to embryonic lethality (this is
called “tissue rescue”). One example of this is the Rb-null
mouse. Rb−/− mice die after 13 days of gestation, so the
physiological role of Rb in the prostate could not be ade-
quately determined in adult male mice. Consequently, pelvic
organ rudiments from Rb null mice were grafted under
kidneys of adult male nude mice [82]. The grafts formed
well-diﬀerentiated epithelial prostate ductal structures. Mice
containing wild-type (WT) Rb grafts and mice containing
null Rb grafts were both treated with testosterone propionate
andestradioltoinducecarcinogenesis.Upontreatment,both
WT and null grafts displayed hyperplasia, but only the Rb
null grafts developed atypical hyperplasia and cancer. This
model validates the tumor suppressive activity of Rb in the
prostate, which would not have been possible using the
whole body knockout model. Another example of tissue
rescue from an embryonically lethal mouse is the p57(Kip2)
model [83]. Urogenital tissue was microdissected from p57
knockout mice and grafted under the kidney of nude mice
[84]. The tumors that resulted had many similarities to
human PCa, especially in terms of the kinetics of tumor
development and diﬀerentiation patterns. This model was
not only important to determine p57’s role in PCa but
also may be an easily adaptable model for future molecular
studies.
Intratibial and intrafemoral injections have been used to
model the invasion and growth of PCa cells in bone, pro-
viding a platform for studying bone microenvironment and
bone-tumor crosstalk, which is essential to understanding
why PCa tumors so frequently metastasize to the skeleton.
The reason these models are so valuable is because there is
no mouse model that spontaneously metastasizes to bone.
Intratibial injections were ﬁrst described for PCa in 2002,
when cells from three PCa cell lines were injected into the
tibiae of nude mice to compare their relative ability to invade
a n dg r o wi nb o n e[ 85]. Cells may also be genetically altered
to study the eﬀect of speciﬁc genes on the ability of cells
to grow in bone. This was demonstrated in 2005 when the
WntantagonistDKK1(Dickkopf1)wasknockeddownusing
short hairpin RNA (shRNA) in PCa cell lines, and these
cells were then injected into the tibiae of SCID mice [86].
Intrafemoral injections can also be used in the same context
as intratibial injections. Femurs are larger than tibiae in
overall size and cavity size, so it depends on the situation
as to which bone is chosen for injection. As an example,
Fizazi et al. injected human MDA PCa 2b cells into femurs of
SCID mice to determine the mechanism by which these cells
form osteoblastic lesions in bone [87]. Intrabone injections
represent an important model for the elucidation of the
importance of genetic pathways and other factors in PCa
metastasis to bone.
Summary. Despite the utility of the xenograft systems, there
are limitations to their use [49]. A compromised immune
system, while it is required to allow growth of foreign
tissues in mice, raises concerns about how accurately these
mice model tumor progression. The interaction between
immune cells and tumor cells may play an important role
in human PCa metastasis [88], and the metastasis that
takes place in the absence of an immune system may be
misleading. In addition, in bypassing the normal process
of tumor initiation and/or the steps required for metastasis
by using cells established from metastatic sites, the process
of angiogenesis and interaction with the microenvironment
maynotbeaccuratelymodeled.Orthotopicimplantationhas
been suggested to represent a more accurate environment for
the progression of PCa [89]. The use of orthotopic tissue
implantation addresses some of the limitations listed above
but does not completely recapitulate the normal processes
of tumor development. However, xenograft systems have
beenimportant,andsometimesessential,todeterminemany
physiologically pertinent results, such as the way diﬀerent
cells interact, or the diﬀering tumorigenicity or metastatic
capacity of speciﬁc cell populations.
3.2.2. Transgenic T Antigen Models. Genetically engineered
mouse models (GEMMs) have allowed for the development
of mice carrying genetic modiﬁcations equivalent to those
associated with human tumors. This has not only validated
the importance of these alterations in tumor initiation and
progression but has also allowed for the development of
improved models of therapeutic eﬃcacy for several human
tumors. The ﬁrst methods developed to genetically modify
mice involved the introduction of DNA constructs designed
to induce the expression of proteins under the control of
tissue-speciﬁc promoters. This method was ﬁrst used to
model PCa in mice via the ectopic expression of simian
virus 40 (SV40) Large T antigen (Tag) in the prostate. This
approachresultedintherandomintegrationofthetransgene
in the mouse genome and did not allow inactivation of
gene expression. SV40 T antigens were used because of
their transforming ability [90]. The large T antigen acts
as an oncoprotein via suppressive interactions with the
tumor suppressor proteins p53 [91] and retinoblastoma
(Rb) [92] whereas the small t antigen interacts with the6 Prostate Cancer
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serine/threonine-speciﬁcproteinphosphatase2a(PP2a)[93]
to induce transformation. However, because SV40 has not
been observed to induce PCa in humans, the clinical
relevance of the transforming actions of these antigens in
mice is debatable.
C3(1)-Tag. The ﬁrst published mouse model inducing the
expression of SV40 tumor antigens to develop PCa in the
mouse was the C3(1)-Tag model in 1994 [94]. A review writ-
ten soon thereafter discussed the genetic alterations that take
place during the development of prostate cancer in this ﬁrst
transgenic model of multi-stage PCa [95]. The researchers
targetedtheexpressionoftheSV40largetumorantigen(Tag)
to the prostate by using a region of the C3(1) gene, which is
formally known as the rat prostatic steroid binding protein
gene. Male C3(1)-Tag mice developed prostatic epithelial
hyperplasia as early as 3 months of age, and the majority
of males developed locally invasive adenocarcinoma by 7–11
months of age. Tumors rarely metastasized, and those that
did went to the lung. However, the expression of Tag was not
speciﬁc to the prostate; two-thirds of female mice developed
mammary adenocarcinoma by 12 weeks of age, and they
correlated to SV40 transgene expression. SV40 expression
was also detected in the salivary gland and testes. The fact
that it took months for mice to develop adenocarcinoma
after the ﬁrst appearance of PIN suggests that genetic factors
besides Tag expression, such as loss of p53, were responsible
for transformation [95]. The strategy of expressing SV40
tumor antigens to the prostate using prostate-speciﬁc genes
was used in several later models with more eﬀective prostate
targeting.
TRAMP. One of the most well-known prostate cancer
mousemodelsistheTRAMP(transgenicadenocarcinomaof
the mouse prostate) model, which was generated and char-
acterized in 1995–1997 [96–98]. In this model, expression
of both the large and small SV40 tumor antigens (T/tag)
was regulated by the prostate-speciﬁc rat probasin promoter
(rPB, now commonly referred to as PB). This was the
ﬁrst in a line of PB expression cassettes, each containing
slightly diﬀerent lengths of the promoter and 5  untranslated
region (UTR); this particular construct contained 426 base
pairs (bp) of the PB promoter as well as 28bp of the
5  UTR (signiﬁed as −426/+28) [97, 99]. We will discuss
the other PB expression cassettes later in the article. The
success of the TRAMP model was that it was able to induce
transgene expression speciﬁcally in the prostate (due to
the androgen-regulated prostate-speciﬁc expression of PB)
whereas previous and future models expressed the transgene
in other organs.
TRAMPmicedevelopedepithelialhyperplasiaby8weeks
of age (corresponding to sexual maturity), progressed to
prostatic intraepithelial neoplasia (PIN) by 18 weeks of age,
and after 28 weeks of age, 100% of the mice displayed lym-
phatic metastases, and approximately two-thirds displayed
pulmonary metastases. Thus, TRAMP was the ﬁrst mouse
model to display distant organ metastases, albeit rarely
to the skeleton. This model was also the ﬁrst GEMM to
display castration-resistant disease. Castration of mice at 12
weeks of age did not aﬀect primary tumor development or
metastasis in the majority of TRAMP mice. In mice that
developed primary tumors despite castration, twice as many
displayed lymphatic or pulmonary metastases relative to
noncastrated mice, indicating that the mice that develop PCa
after castration are predisposed to develop more aggressive
and more poorly diﬀerentiated disease [96]. An issue with
the TRAMP model is that the most frequent malignancy in
these mice has been reported to be of neuroendocrine origin
[100]. Some neuroendocrine markers are found in human
PCa, but the majority of cells in prostate adenocarcinoma
are epithelial. It is possible that the simultaneous loss of
p53 and Rb could increase susceptibility to neuroendocrine
cancer [100]. Overall, the TRAMP model may still be
suitable for studying PCa, but it may only be clinically
relevant for a small population of patients that develop PCa
of neuroendocrine origin, or perhaps for those who have
extensive neuroendocrine diﬀerentiation [101].
FG-Tag. The fetal globin-γ/T-antigen (FG-Tag)m o u s e
model was originally developed (concurrently with several
otherless-speciﬁcmouselines)in1996[102]andwasfurther
characterizedayearlater[103].Amolecularcharacterization
of the FG-Tag model has also been published [104]. At the
time, the fetal globin-γ gene was thought to be speciﬁcally
expressed in embryonic erythroid cells based on studies in
transgenic mice [105], and the authors of the study were
initially interested in these erythroid cells. They generated
eight mouse lines using the human FG promoter. In one line
(referredtoasGγ/T-15),theysawformationofpalpableuro-
genital tumors at 16 weeks and highly vascularized prostate
tumorsin50% ofmalemiceat5–7 months ofage.Malemice
also displayed metastasis to the renal lymph nodes, adrenal
glands, and kidneys, along with infrequent micrometastasesProstate Cancer 7
to the lung, bone, and thymus. Transgenic male mice were
castrated at 4–6 weeks of age (sexual maturity) and prostate
tumors still formed, a sign of castration resistance. In the
female transgenic mice, adrenocortical tumors were seen in
50% of the mice that were surveyed, indicating that the
FG promoter used to express T antigen was not prostate
speciﬁc. In fact, when the model was developed, the PCa
phenotype was not expected and occurred rather randomly
along with phenotypes in other tissues. A followup study
of the FG-Tag model found that Tag expression occurred in
p63+ basal cells, but neuroendocrine diﬀerentiation still took
p l a c ei na d v a n c e dt u m o r s[ 106]. Overall, this mouse line is
a fairly accurate model for the study of castration resistant
PCa, but its oﬀ-target eﬀects may play a critical role in
carcinogenesis.
LADY. The LADY series of models, developed in 1998, is
similar to the TRAMP model in that the PB promoter drives
SV40 T antigen expression [107], but there are two key mod-
iﬁcations. The creators of these models recognized that while
expression with the PB promoter was suﬃciently prostate
speciﬁc, the transgenic expression level was variable between
the previously developed mouse lines. They had shown
that a larger fragment of the PB promoter (LPB) could be
used to cause consistently high transgene expression [108].
This LPB cassette (also known as the second generation PB
promoter) contained 11,500bp from the PB promoter and
28bp from the 5  UTR (−11,500/+28). This LPB promoter
was subsequently utilized to express T antigen. The second
key diﬀerence in this model is that the LPB promoter was
linked to a deletion mutant of the SV40 T antigen that
expressedonlythelargeTantigenandnotthesmalltantigen.
Seven transgenic lines were then established and split into
three groups based on the stage of neoplasia attained and
how fast the cells became hyperplastic. All male mice
developed prostate tumors, but the fastest line to do so was
designated 12T-7f. This line was the only one to develop late-
stage adenocarcinoma. The cancer started as small foci of
hyperplasia, followed by proliferative overgrowth, dysplasia,
HGPIN, and ﬁnally adenocarcinoma, representing an ideal
model for studying the various stages of PCa. Tumors from
the 12T-7f line regressed upon castration but were restored
after administration of androgen. According to a later article,
some mice developed metastases to the lymph nodes, liver,
and lung in the 12T-10 line, but this line also showed a
more neuroendocrine phenotype [109]. The LADY model
mo v edPC amousemod elingf o rwar dd uet oitsmo r especiﬁc
targeting and increased levels of transgene expression in the
prostate. Also, the LADY models more accurately mimic the
majority of human PCa because the cancer is slow growing
and has a mostly epithelial phenotype. However, castration
resistance and metastasis are not modeled well.
Because type II transmembrane serine protease hepsin
mRNA has been shown to be upregulated in the majority
of PCa tumors [110, 111], a PB-hepsin construct was placed
with the LPB-Tag construct used in the LADY 12T-7f model
such that both the large T antigen and the hepsin transgene
were expressed speciﬁcally in the prostate. Laminin-332 has
been shown to act as a substrate for hepsin, which may
increase migratory ability [112]. This double transgenic
model was developed in 2004 [113]. The PB used to express
hepsin was of the third generation of PB promoters. It
is known as ARR2PB because it comprises one copy of
androgen receptor binding site 1 (ARBS-1) and ARBS-
2[ 114]. This cassette is composed of 286bp of the PB
p r o m o t e ra n d2 8 b po ft h e5   UTR (−286/+28) and con-
tains the DNA sequence necessary for androgen-regulated
prostate-speciﬁcexpression.AnaddedbeneﬁtoftheARR2PB
promoter is that it consistently induces higher levels of
transgene expression than its predecessors. LADY 12T-7f
mice do not normally express hepsin, and the addition of
hepsin expression caused disruption and disorganization
of the epithelial structure, leading to invasion and distant
metastasis in 55% of male mice after 21 weeks. Metastases
went primarily to the liver and also to the lymph nodes and
skeleton. The metastatic lesions were, however, determined
tocontainmainlyneuroendocrinecells,whichisinconsistent
with human metastases. This model opened possibilities of
inducing metastasis in models that normally do not show
metastasis, and doing so by the expression of a gene that has
been detected in human PCa (hepsin), which is ideal.
CR2-Tag. In1998,theCR2-Tag modelwasdeveloped,which
placed Tag expression under the control of a segment of the
cryptdin-2 (CR2) gene after it was discovered that CR2-Tag
male mice of diﬀering pedigrees were dying unexpectedly
of large prostate tumors at 5–7 months of age [115]. The
creators of this model were originally studying intestinal
epithelial cells (Paneth cells) that secrete antimicrobial
peptides called cryptdins [116]. When Tag expression was
induced in Paneth cells via CR2, the cells died and did
not cause any abnormal intestinal phenotypes in the mice;
however, prostate tumors formed. By 12 weeks of age, all
malemicedisplayedPIN,andby24weeks,everymalemouse
displayed locally invasive PCa. Mice displayed metastases to
the liver, abdominal lymph node, lung, and bone marrow.
These tumors were also castration resistant. However, Tag
expression was once again being induced in neuroendocrine
cells, which were extremely tumorigenic in this model. To
further the molecular description of the prostatic neuroen-
docrine cells in this model, laser microdissection was later
performed for functional genomics analysis [117].
PSP94-Tag. To establish an additional vector gene system for
the study of PCa, the PSP94-Tag model (known as TGMAP,
for transgenic mouse adenocarcinoma in the prostate) was
developed in 2002 [118]. PSP94 refers to the prostate
secretory protein of 94 amino acids, which is one of the
three most abundant secretory proteins in the prostate.
PSP94 was used to express both large and small T antigens
in the prostate. Three founder lines were established (183-
2, F0183-3, and F0186-9). Line 183-2 was similar to the
TRAMP model, while the other two were similar to the
LADY model. Metastatic PCa was found in some of these
mice in the lymph node and kidney. Some tumors regressed
after castration, but a population of mice was eventually
castration resistant. However, the TGMAP model showed
variable phenotypes and genomic variability. Therefore, in8 Prostate Cancer
2005, a new PSP94-Tag model was created using a novel
gene-targeting method; it was called the knockin mouse
adenocarcinoma of the prostate (KIMAP) model [119].
KIMAP was a better model in that all male mice developed
slowly progressing PCa synchronously, there was a higher
tumorpenetrance,neuroendocrine diﬀerentiationwasrarely
seen, and it mimicked human disease in other aspects [120].
The KIMAP model is the most comparable to human disease
out of the models expressing SV40 Tag, especially because of
its relative lack of neuroendocrine diﬀerentiation.
3.2.3. Other Transgenic Models
Mt-PRL. Mt-PRL was created in 1997 to determine the
physiological role of the polypeptide prolactin (PRL) in the
prostate gland [121]. PRL levels increase with age and during
prostate hyperplasia [121]. The prostate also expresses
PRL receptor, and various eﬀects have been observed in
the prostate upon PRL activation [122]. Therefore, the
contribution of PRL expression to PCa is unclear. The
metallothionein-1 (Mt-1) promoter was placed upstream of
the PRL gene to induce its expression. Mt-1 expression is not
restricted to the prostate, however, meaning that expression
of PRL was being directed to any tissue that naturally
expresses Mt-1 [123].PRLtran sg e n ee xp r essi o nwasd et ect ed
in the liver, thymus, kidney, pancreas, seminal vesicles, testes,
and prostate. The authors knew that PRL was important in
mammary gland development, but they wished to determine
the role of PRL in the prostate [121]. All prostates examined
were enlarged, and all were hyperplastic with increased
stroma as well as nuclear polymorphism. Testosterone levels
were increased in Mt-PRL mice. No metastasis or castration
resistance was reported. This model would be more appro-
priate for benign prostatic hyperplasia (BPH) than for PCa.
To more accurately elucidate the mechanism of PRL in PCa,
a more prostate-speciﬁc promoter should be used in future
models.
BK5-IGF1. Soon after the LADY and CR2-Tag models were
being developed, a transgenic mouse model was created that
overexpressed the insulin-like growth factor 1 (IGF1) under
control of the bovine keratin 5 (BK5) promoter [124, 125].
It had been shown that elevated IGF1 expression was an
indicator of PCa, even in some cases in which PSA levels are
normal [126]. The creators of this model originally chose the
B K 5p r o m o t e rt oi n d u c eI G F 1e x p r e s s i o ni no r d e rt os t u d y
the speciﬁc role of IGF1 in carcinogenesis in the basal layer
of the epidermis. BK5 is expressed in the basal epithelial
layer of multiple tissues, including (but not speciﬁc to) the
prostate. They found prostatic hyperplasia in mice as young
as 2 months. After 6 months, mice displayed hyperplasia,
dysplasia, and PIN in all prostatic lobes and adenocarcinoma
after 9 months. Some neuroendocrine diﬀerentiation was
detected. The prostate tumor cells were locally invasive but
didnotmetastasizenorweretheycastrationresistant.Similar
to the Mt-PRL model, the BK5-IGF1 model may be adequate
to model prostate disease, but the oﬀ-target eﬀects of the
transgene would be cause for concern when interpreting
results.
PB-mAR. The purpose of the PB-mAR model, developed
in 2001, was to determine the direct eﬀect of the androgen
receptor (AR) on the prostate epithelium [127]. This may
seem unusual, considering that it was already well known
that the majority of PCa cases are androgen dependent
for tumor growth and indeed express AR, and drugs were
already being manufactured to ablate AR activity [128].
However, before this, no animal model had been created
to directly test the eﬀects of AR overexpression. Murine AR
(mAR) expression was placed under control of the ﬁrst gen-
eration PB promoter (−426/+28). All male mice displayed
hyperproliferation, neoplasias, and eventually microinvasive
HGPIN, indicating that AR is a positive regulator of cellular
proliferation and that mouse prostates are more susceptible
to PCa upon AR overexpression. However, a more recent
ﬁnding suggests that the loss of AR expression in the mouse
prostate via PB-Cre recombination also results in increased
epithelial proliferation [129]. Therefore, more needs to be
learned about the mechanism of how AR behaves in the
prostate. This model would be valuable in future AR studies,
especially in terms of castration resistance.
ARR2PB-Myc. The functional role of Myc in PCa is
unknown, but it has been found to have an increased gene
copy number in approximately 30% of human PCa cases
[130, 131]. Therefore, to determine the eﬀect Myc has in
the prostate, a model was generated in 2003 [132]. The PB
promoter (−426/+28) was used to generate mice with low
Myc expression (“lo-Myc”), and the ARR2PB promoter was
used to generate mice with high Myc expression (“hi-Myc”).
The hi-Myc mice displayed progression from PIN to invasive
carcinoma as early as 3 months whereas the lo-Myc mice
displayed the transition at 10 months, indicating a dosage-
dependent response to the Myc transgene. This data also
implies that the two PB promoters have diﬀering ability to
induce transgene expression. Upon castration at 2 months,
all mice showed complete regression of PIN. When mice
with PCa were castrated at 8 months, tumors regressed, but
the mice displayed residual tumors up to 5 months after
castration. Thus, it seems that early in the progression of
PCa, androgen ablation is fully eﬀective, but after the cancer
has had time to develop, androgen ablation is less eﬀective.
No metastasis was observed in this model, so ARR2PB-
hepsin transgenic expression was added to the Myc model
by crossing PB-hi-Myc to PB-hepsin mice to determine if
metastases would result (this was the same strategy used in
theLADYmodel) [133]. Thesebigenic mice displayed higher
grade carcinoma and swifter tumor progression but did not
developanymetastases.AlloftheMycmodelsalsodeveloped
adenocarcinoma, rather than neuroendocrine carcinoma.
These models would be most practical for studying early
progression of PCa and stand to contribute to Myc research
in PCa.
ARR2PB-FGFR1. In 2003, the physiological roles of ﬁbrob-
last growth factor receptors 1 and 2 (FGFR1 and 2) in the
prostate were determined [134]. FGFR1 had been shown to
be upregulated in 40% of poorly diﬀerentiated PCa [135].Prostate Cancer 9
The founder lines were called JOCK1 and JOCK2, respec-
tively. What separates these models from others is that they
used chemically induced dimerization (CID) technology to
regulate FGFR signaling. Treatment with AP20187 induced
signaling in the mice, and withholding treatment stopped
signaling. FGFR2 signaling did not have an eﬀect whereas
FGFR1 signaling induced pronounced hyperproliferation
and PIN, which was reversible until neovascularization
occurred. This indicates the importance of FGF signaling in
PCa. Two downstream targets of FGFR1 (ERK1 and ERK2)
were activated via phosphorylation and translocated to the
nucleus in regions of hyperplasia and progression. The PB-
FGFR1 model represents a good model for early stages of
PCa but fails to recapitulate more aggressive aspects of the
disease. Crossing mice from this model to other mice may
induce metastasis and provide information about possible
synergism between the FGF pathway and other molecular
signaling pathways.
PB-Ras. PB-Ras mice were generated in 2004 to test the
eﬀects of oncogenic H-Ras on the prostate [136]. Ras
has been implicated in many cancers and works through
many downstream eﬀectors (including the MAP kinase
pathway) to induce proliferation, cell survival, and growth.
A mutation at residue 12 (Rasval12) changing the amino acid
to a valine causes Ras to become constitutively active, and
expression of this version of Ras was placed downstream of
PB (−426/+28). Activated Ras has been detected in human
PCa, but it has been suggested that Ras mutations are rare
and therefore insigniﬁcant in PCa [137–139]. Male mice did
not progress further than PIN. Other phenotypes included
intestinal metaplasia and thickened ﬁbromuscular stroma.
This model, similar to the PB-FGFR1 model, indicates that
Ras may be important in early PCa transformation but may
not be as important in later stages.
PB-Neu. Neu (also known as ERBB2 or HER2) has been
implicated in various cancers and is best known for its
strong correlation with a subtype of breast cancer [140]. In
2006, a novel PB promoter was utilized to induce expression
of a constitutively active version of Neu; the PB used
was 4,500bp [141]. All sacriﬁced male mice displayed at
least one of three prostate phenotypes: hyperplasia, PIN,
or PCa, depending on the age at sacriﬁce. Only 7 of 60
(11.7%) mice developed PCa. Of the mice that developed
PCa, ﬁve displayed considerably enlarged prostates that
included recruitment of ﬁbroblasts and angiogenesis, but no
invasion or metastasis was apparent. Histopathologically, the
carcinoma that developed in this model is similar to the
a c i n a rt y p ei nh u m a n st h a ti sb e l i e v e dt ob ed e r i v e df r o m
luminal epithelial cells. Neu expression in human PCa has
been detected, but the frequency of samples that express Neu
is debatable and has been reported anywhere from 10 to
41% of cases [141]. This model shows that Neu activation
can induce PCa in mice. Therefore, PB-Neu could serve as
a valuable model for elucidating the tumorigenic signaling
through Neu, but it remains to be seen whether it will have
physiological signiﬁcance in human PCa.
ARR2PB-ERG. The fusion between transmembrane pro-
tease, serine 2 (TMPRSS2) and ETS-related protein (ERG)
is the most common fusion that takes place in the ERG gene.
The TMPRSS2-ERG fusion protein is positively expressed in
approximately 50% of human PCa cases [142]. When the
genes become fused, the noncoding exon 1 of TMPRSS2
is placed next to exon 2 of ERG, resulting in a truncated
ERG product. In 2008, a mouse model was created that
placed this ERG product under control of the ARR2PB
promoter [142]. The mice developed PIN by 12–14 weeks
of age at a frequency of about 38%. This suggests that the
TMPRSS2-ERG fusion protein is not suﬃcient to induce
PCa, but this model must be evaluated at later timepoints
to validate this assertion. Other groups have also generated
transgenic ERG models with mixed results [143–145]. Only
a small percentage of the mice developed low grade PIN,
and most mice did not develop PIN; the authors suggest
that the interpretation of the histology may be the reason for
varying results and that the PIN in the ARR2PB-ERG model
was rather subtle. A novel ﬁnding that came out of these
studieswasthatconcomitantTMPRSS2-ERGexpressionand
loss of PTEN or activation of the PI3K pathway results in
more aggressive PIN that appears at an earlier age. Carver
et al. showed that transgenic ERG expression coupled with
heterozygous Pten expression results in invasive prostate
adenocarcinoma in mice [143]. Taking these results together,
it appears that ERG fusion proteins have a subtle role
in prostate tumor initiation and may cooperate with the
PI3K pathway to induce tumorigenesis, but more needs
to be done to fully elucidate the molecular mechanisms
involved.
Summary. All the transgenic models discussed thus far show
an interesting phenomenon: while SV40 T antigen is not
normally expressed in human PCa, its induced expression
generally causes particularly aggressive, metastatic, and
castration resistant PCa (Table 1). However, when other
oncogenes (which may or may not be expressed in human
PCa cases) are expressed speciﬁcally in the prostate, the
resulting phenotype is mild and rarely progresses to adeno-
carcinoma(Table 2).ThisismostlikelyduetotheTantigen’s
negative eﬀects on p53 and Rb (which is generally only seen
in late disease in humans), which also probably accounts
for the neuroendocrine phenotype. Transgenic models have
so far not been able to accurately induce all stages of
epithelial PCa in a mouse using an endogenously expressed
gene. This is most likely because PCa probably requires
more than one genetic event involving multiple molecular
pathways. There is much work to be done to interpret and
validatetheﬁndingsfromthismultitudeoftransgenicmouse
models.
3.2.4. Traditional Knockout Models
Traditional (or whole-body) knockout models represent a
diﬀerent strategy for determining the roles of important
genes in PCa. Tumor suppressor genes (or regions of DNA
essential for their activity) are excised in knockout models.
Historically, these models were valuable in determining10 Prostate Cancer
Table 1: Prostate cancer mouse models utilizing T antigen.
Model Year Other tissues aﬀected Metastasis sites Cell of origin Castration
resistance References
C3(1)-Tag 1994 Mammary gland, testes, salivary
gland Infrequently to the lung Epithelial Not determined [94, 95]
PB-T/tag
(TRAMP) 1995 None LN, lung Neuroendocrine Yes [96–100]
FG-Tag 1996 Adrenal gland, adipose tissue LN, adrenal glands, kidneys Neuroendocrine Yes [102–
104, 106]
LPB-Tag
(LADY) 1998 None LN, liver, lung Neuroendocrine No [107–109]
CR2-Tag 1998 Paneth (intestinal epithelial) cells LN, lung, liver, bone marrow Neuroendocrine Yes [115–117]
PSP94-T/tag
(TGMAP &
KIMAP)
2002 None LN, kidney Epithelial & rarely
neuroendocrine Yes [118–120]
LPB-
Tag/ARR2
PB-hepsin
2004 None Lung, liver, bone Neuroendocrine Not determined [113]
Table 2: Prostate cancer transgenic mouse models.
Model Year Other tissues aﬀected Highest stage of
neoplasia
Castration
resistance References
Mt-PRL 1997 Liver, thymus, kidney, pancreas, seminal vesicles, testes Benign hyperplasia No [121–123]
BK5-IGF1 2000 Basal epithelial cells Adenocarcinoma No [124, 125]
PB-mAR 2001 None HGPIN Not determined [127]
ARR2PB-
myc 2003 None Adenocarcinoma Partial [132]
ARR2PB-
FGFR1
(JOCK1)
2003 None Hyperplasia No [134]
PB-Ras 2004 None PIN No [136]
PB-neu 2006 None Adenocarcinoma Yes [141]
ARR2PB-
ERG 2008 None PIN Not determined [142–145]
ARR2PB-
hepsin/
ARR2PB-
myc
2010 None Adenocarcinoma Partial [133]
embryonically lethal genes. If, after a gene was knocked
out, the embryo did not survive, the gene was considered
embryonically lethal and therefore critical in development;
however, embryonic lethality precluded the widespread use
of knockout models for cancer. When a traditional knockout
is created, the gene of interest is knocked out ubiquitously,
so it is diﬃcult to determine the organ-speciﬁc roles of
that gene. Traditional knockouts are generally made via
homologous recombination in embryonic stem cells (ESCs).
This process was ﬁrst described in 1989, and the develop-
ments leading to this were recognized with the 2007 Nobel
Prize in Physiology or Medicine [146]. Readers will notice
that these knockout models, even when PCa is observed,
have generally not been tested for castration resistance. For
complete analysis of these models, such tests should be
performed.
RARγ. The retinoic acid receptor gamma (RARγ)w a s
knocked out to make a mouse model in 1993 [147]. The
purpose of the model was to determine unique functional
roles of RARγ receptors, with little thought to prostate
phenotypes (although the RAR family had been suggested
to be important in organogenesis). RARγ family member
expression had been shown via in situ hybridization to be
limited to several tissues in the embryo and in the skin of
the adult. A study from 2000 showed that various RARs
(including gamma) are expressed in a majority of the PCa
samples that were tested [148]. Eight out of 8 male mice
developed squamous cell metaplasia in the prostate and
seminal vesicles and were unable to impregnate female mice.
There were also developmental issues in the prostate, evident
in the lack of normal mucosal folds, septa characteristics,
and secretory products. A vast array of phenotypes wasProstate Cancer 11
observed in these mice, but carcinoma was not detected, and
metastasis and androgen dependence were not checked. This
is not a good model for PCa.
p27. Three groups simultaneously published the generation
of a p27 (also known as Kip1) knockout mouse in 1996,
but they did not include analysis of prostatic tissue [149–
151]. p27 is a tumor suppressor that plays a role in G1
phase arrest during the cell cycle. In 1998 this model was
examined for eﬀects on the prostate because distinct p27
expression patterns had been identiﬁed in human PCa
samples, and loss of p27 seemed to correlate to more
aggressive PCa [152]. p27 knockout mice display hyperplasia
of multiple organs, aside from other phenotypes (Table 3).
Prostatic hyperplasia was detected in acinar epithelial cells
upon histological analysis, similar to that seen in human
BPH. Increased proliferation, enlargement of the glands, and
increased ﬁbromuscular stromal cells were observed, but
metastasisandandrogendependencewasnottested.The p27
mouse may not represent a critically important model for
PCabutmaybeagoodmodelforBPH,asitseemsthatlossof
p27 is causally linked to BPH development in both humans
and mice [152].
Pten. Pten, or “phosphatase and tensin homolog deleted
from chromosome 10” (also known as Mmac1, for mutated
in multiple advanced cancers), is a key tumor suppressor,
and its loss has been linked to many cancers, including a
strongcorrelationinhumanPCa[166].Ptenisaphosphatase
that removes a phosphate group from phosphatidylinositol
3,4,5-triphosphate (PIP3,4,5), thereby downregulating the
Akt-mTOR signaling pathway. In 1998, a Pten knockout
mouse was created by generating a null mutation in the
Pten gene [153]. Another group (in 1999) also generated a
Pten knockout mouse by deleting a slightly diﬀerent portion
of the gene but inducing the same inactivating eﬀect on
Pten [154]. It was found that Pten is essential for early
embryonic development, as no homozygous knockouts were
viable. Heterozygotes, however, were viable and produced
a broad range of phenotypes in multiple tissues (Table 3).
Both models were reported to have enlarged, complex,
hyperplastic prostates, and the model from 1999 reported
the development of PIN. No metastases were reported, and
due to the diﬀuse nature of the eﬀects of Pten inactivation,
castration resistance was not tested. These models showed
that Pten is a critical early regulator of PCa development.
At least three other models have since knocked out
an additional gene simultaneously with the Pten gene in
what are referred to as double knockouts, in which loss of
Pten with other tumor suppressors leads to more aggressive
phenotypes [162, 165, 167]. The ﬁrst model knocked out
both Pten and p27, and 100% of male mice developed PCa,
leading to the conclusion that Pten and p27 have cooperative
roles in the prostate [162]. The second model knocked
out both Pten and Nkx3.1, and extensive hyperproliferative
multifocal lesions were observed, indicating the presence
of HGPIN and adenocarcinoma, which was not observed
in either the Pten or Nkx3.1 models. Also, lymph node
metastasis and castration resistance were reported in this
double knockout [163, 164]. No increase in low-grade PIN
was observed, indicating that the cooperativity of Pten and
Nkx3.1occursatlaterstagesofPCa[167].Finally,whenPten
and p53 (a tumor suppressor that induces apoptosis after
cellular damage) were knocked out together, PIN developed
with a shortened latency, indicating these two tumor sup-
pressors cooperate to accelerate tumorigenesis [165]. Each
of these models displayed epithelial carcinogenesis. Overall,
Pten loss plays an integral role in the development of PCa,
and the models in which Pten is lost will be of great clinical
value for patients with Pten mutations.
Nkx3.1. Nkx3.1 is a transcription factor with tumor sup-
pressingactivityandisthemurinehomologoftheDrosophila
gene bagpipe. Loss of Nkx3.1 is seen often in the early stages
ofPCainhumans[168].In1999,anNkx3.1knockoutmouse
was generated to determine its physiological eﬀects [155].
Several phenotypes were seen in the prostate and seminal
vesicles. Prostates developed hyperplasia and dysplasia that
advanced with age, but no overt tumors were detected.
Prostate epithelial cells were hyperproliferative. Heterozy-
gous Nkx3.1 expression resulted in a less severe form of PIN,
indicating Nkx3.1 haploinsuﬃciency. Upon further exami-
nation of an Nkx3.1 knockout model, morphogenic defects
in the salivary glands were also found [156], indicating
that Nkx3.1 may be important in the development of other
cell types. The data suggests that Nkx3.1 loss is important
for initiating events in PCa but may not be suﬃcient for
progression to advanced stages; this evidence was supported
inalaterpublication[157].Aninterestingobservationisthat
loss of Nkx3.1 disrupts normal prostatic development and
diﬀerentiation, but loss of Nkx3.1 also contributes to PCa.
New evidence suggests that loss of Nkx3.1 increases DNA
damage, such as mutations, thereby creating an environment
for genomic instability and tumorigenesis [169]. Because
Nkx3.1 is downregulated in humans, Nkx3.1 mutant models
are valuable in studying PCa progression.
Stat5a. Stat5a is a transcription factor that mediates signal-
ing through PRL to inﬂuence the development of certain
glands (see the Mt-PRLSection 3.2.3 for more discussion).
A Stat5a-null mouse was generated in 1997, and Stat5a
was shown to be critical in mammary gland formation and
lactogenesis [158]. In 2000, Stat5a was also implicated in
prostatic epithelial growth via PRL and was shown to be
associated with more aggressive PCa in human cases [159,
160]. Therefore, the Stat5a mouse was used to determine
its eﬀect on prostate growth and development [161]. Stat5a
mice showed a speciﬁc epithelial defect in the prostate,
apparentbyacinardisorganizationanddevelopmentofcysts.
They also found that testosterone serum levels were normal
in knockout mice, indicating that regardless of androgen
status, Stat5a deﬁciency will cause developmental defects.
The strategy behind this model is not one we have seen
in previous models. Generally, when a gene is knocked
out, it is to test its tumor suppressive activity, so that
researchers can generate a cancer model. In this model, a12 Prostate Cancer
Table 3: Traditional knockout models.
Model Year Other tissues aﬀected Highest stage of
neoplasia
Castration
resistance References
RARγ 1993 Seminal vesicles, wide array of developmental defects Squamous cell
metaplasia Not determined [147]
p27 1996 Hyperplasia of many organs, infertility in females, pituitary
tumors, increased overall body size
Hyperplasia &
increased stromal cells Not determined [149–151]
Pten 1998 Gonads, germ cells, lymphoid cells, epidermis, uterus,
endometrium, intestine, thyroid, adrenal gland PIN Not determined [153, 154]
Nkx3.1 1999 Salivary glands, bulbourethral gland, seminal vesicles Hyperplasia &
dysplasia Not determined [155–157]
Stat5a 1997 Mammary glands None Partial [158–161]
Pten × p27 2001 Endometrium, intestine, thyroid, adrenal gland Adenocarcinoma Not determined [162]
Pten × Nkx3.1 2002 Similar to Pten and Nkx3.1 models, though only prostate
was reported on LN metastasis Yes [163, 164]
Pten × p53 2009 Similar to Pten model, though only prostate was reported
on HGPIN Not determined [165]
putative oncogene was knocked out to determine if it is
important in the growth and development of the gland.
Later, however, researchers determined in vitro and in vivo
that Stat5 is indeed an important factor in PCa metastases
[170], though no prostate-speciﬁc transgenic Stat5a mouse
has been created.
Summary. Traditional knockouts have been important to
illustrate the role that certain tumor suppressors play in the
prostate, particularly in early transformation. Similar to the
transgenic models, the knockouts suggest that loss of any
one gene is not suﬃc i e n tt or e s u l ti nP C aa n dt h a tm u l t i p l e
genetics events are required. However, because these models
employ a whole-body knockout, it is diﬃcult to conclude
that any of these genes play a prostate-speciﬁc role due to
the wide range of physiological responses that might take
place in other tissues or cells that may aﬀect carcinogenic
transformation. Also, a whole-body knockout does not
accurately recapitulate what generally happens in a human
cancer(unlessamutationisinheritedthroughthegermline).
It is commonly believed that genes are mutated or lost in
one cell, allowing it to obtain “hallmarks of cancer,” [171]
thereby eventually creating a tumor. A ﬁnal issue with the
traditional knockout is that if a gene is required for normal
development of the organism, knocking it out will result in
embryonic lethality, which does not allow for further study.
Therefore, a more tissue-speciﬁc gene knockout model may
yield more interesting and physiologically relevant results.
3.2.5. Conditional Knockout Models
The Cre-loxP System. The Cre-loxP system was developed
in bacteriophage in Sternberg’s laboratory almost 30 years
ago [172, 173]. “Cre” is a gene that “causes recombination,”
and “loxP” is a 34-base pair “locus of phage crossing over”
[173]. Cre is a recombinase protein that promotes speciﬁc
genetic recombination in trans at loxP sites. At ﬁrst, the Cre-
loxP system was characterized via isolation of DNA from
plaque-forming P1 phage that was able to infect Escherichia
coli. Eventually, the Cre-loxP system was used for genetic
recombination in eukaryotic cells, ﬁrst in yeast and later in
mice [174]. The system was further revised so that Cre could
be fused to a mutated version of the estrogen receptor, which
allowed Cre recombination to be dependent on tamoxifen
treatment, rather than on estradiol [175].
The Cre-loxP system is now used extensively in mouse
models for cell type-speciﬁc and tissue-speciﬁc genetic
alterations. Mice that express the Cre recombinase under
the control of a tissue-speciﬁc promoter are crossed with
mice that express a nonspeciﬁc “ﬂoxed” genetic region,
meaning that the region is ﬂanked by loxP sites (Figure 4).
Cre cuts through the loxP sites and excises any region of
DNA in between, leaving behind a single loxP site. This
speciﬁc recombination can either activate or inactivate a
gene, depending on what genetic region is being removed.
An essential exon for a gene’s activity may be removed,
rendering the gene inactive or “conditionally knocked out.”
Alternatively, signals that prevent gene expression (a “stop”
s i t e )m a yb er e m o v e du p s t r e a mo fam u t a t e dg e n e ,c a u s -
ing the transcription of a constitutively active form of a
protein. Examples of these will be discussed in subsequent
paragraphs. Conditional targeting of genes avoids oﬀ-target
eﬀects and developmental issues, and it allows for both
alleles of the genes of interest to be knocked out without
theproblemofembryoniclethality.Anotheraddedbeneﬁtto
conditional models over other GEMMs is that they are able
to add precision that was previously unattainable, especially
in the transgenic models which randomly integrated into the
genome. Due to the large number of conditional knockout
models,wewilldiscussthediﬀerenttypesofprostate-speciﬁc
Cre that have been used to generate models and then discuss
some of the individual models that have been created. Note
that all of the conditional knockout models we discuss have
been generated in the last 10 years (Table 4).
PSA-Cre. Prostate-speciﬁc antigen (PSA) is a serine protease
that is almost exclusively expressed in prostatic luminal
epithelial cells in the human prostate [191]. PSA serumProstate Cancer 13
Table 4: Conditional knockout models.
Model Year Other tissues aﬀected Highest stage of neoplasia Castration
resistance References
PSACreNkx3.1flo x 2002 None PIN Not
determined [176]
PSACrePtenflox 2005 None Infrequent LN metastasis No [177]
PBCre4Ptenflox 2003 None LN & lung metastasis Yes [178, 179]
PBCreRbflox 2004 None Hyperplasia Not
determined [180, 181]
PBCre4LSL-Ph15LO-1
(FLiMP) 2006 None PIN Not
determined [182]
PBCre4p53flo xRbflox 2006 None LN, lung, liver & adrenal
glands metastasis Yes [180, 181]
PBCre4Apcflox 2007 None Adenocarcinoma Yes [183]
PBCre4IGF-1flox 2008 None Hyperplasia No [184]
PBCre4Catnblox(ex3);
K-rasLSLV12 2009 Bulbourethral gland, preputial gland,
and urethral gland metaplasias, testes Adenocarcinoma Putative [185]
PBCre4Catnblox(ex3) &
Nkx3.1CreCatnblox(ex3) 2009 None HGPIN Yes [186]
PBCre4Brca2floxp53flo x 2010 None HGPIN Yes [187]
MMTVCreCatnblox(ex3) 2003
Skin, salivary glands, epididymis, vas
deferens, seminal vesicle, spleen,
mammary tissue
Hyperplasia & metaplasia No [188]
MMTVCrePtenflox 2004 Mammary tissue, skin, lymphocytes,
oocytes, seminal vesicles, salivary glands HGPIN No [189]
FSP1CreTGFβflo x 2004 Fibroblasts, particularly in skin and
stomach PIN Not
determined [190]
Nkx3.1CreERT2Ptenflox 2009 Unknown Adenocarcinoma Yes [16]
levels are used to clinically diagnose PCa. These facts
make the PSA promoter a strong candidate to induce
targeted Cre expression in the prostate. PSA-Cre mice
may be mated with any mouse having a ﬂoxed genetic
region to induce genetic deﬁciency of that region. PSA-Cre
mice have been used to conditionally knock out Nkx3.1
expression (PSACreNkx3.1flo x)[ 176] and Pten expression
(PSACrePtenflox)[ 177]. PSA-Cre activity was observed in
all prostate lobes but in no other tissue tested. Mice in
the PSACreNkx3.1flo x model displayed hyperproliferation,
hyperplasia, and PIN, which supports the idea that Nkx3.1 is
importantinearlystagesofPCa,butperhapsnotlaterstages.
Whereas the ubiquitous Pten knockout models reported
PIN as the most severe eﬀect observed, the conditional
Pten knockout model reported hyperplasia, PIN, invasive
carcinoma, and infrequent lymph node metastases. The
results obtained from these models may more accurately
represent the physiological roles of the respective genes
in the prostate and, therefore, provide stronger evidence
for the clinical relevance of these genes in PCa. These
models display epithelial carcinogenesis, and because these
genes are commonly mutated or lost in human cancers,
these models provide a stable platform for the study of
PCa progression. The lack of skeletal metastases, however,
limits these particular models to study of earlier stages of
PCa.
Probasin-Cre. The PB promoter was extensively used in the
SV40 T antigen models and has been shown to be prostate-
speciﬁc on numerous occasions. We have discussed the
ﬁrst, second, and third generations of the PB promoter.
Two version of Probasin-Cre have been generated, one
using the −426/+28PB, known as PB-Cre [192], and the
other using the ARR2PB, commonly known as PB-Cre4
(the speciﬁcity of PB-Cre4 to prostate epithelial cells avoids
the neuroendocrine phenotype) [193]. We will collectively
refer to them as Probasin-Cre, but will speciﬁcally use the
PB-Cre and PB-Cre4 terminology for individual models.
Probasin-Cre has been the most widely used promoter in
PCa conditional knockout models. Genes that have been
knocked out using Probasin-Cre include Pten [178, 179], Rb
[180, 181], p53 [180, 181], Apc [183], IGF-1 [184], and Brca2
[187].Probasin-Crehasalsobeenusedtooverexpresscertain
oncogenes by excising a STOP codon upstream of the gene,
such as with Kras [185], Catnb [185, 186], and Alox15 [182].
We will discuss a few of these models here; see the original
articles for more detail (Table 4).
Two models were created knocking out the Rb tumor
suppressor in the prostate [180, 181]. When Rb was knocked
out alone (PBCreRbflo x), the most severe prostate phenotype
observed was hyperplasia with loss of integrity of the
basement membrane, suggestive of preinvasive lesions [180].
The conclusion was that Rb loss alone was not suﬃcient to14 Prostate Cancer
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Figure 4: Schematic diagram of the Cre-loxP system.
cause transformation. A similar conclusion was drawn from
aconditionalp53knockout[181].WhenRblossandp53loss
were coupled (PBCre4Rbflo xp53flo x), metastatic carcinoma
resulted [181]. Prostate tumor tissue invaded surrounding
tissues, including adipose tissue, muscle, blood vessels, blad-
der, and urethra, and distant metastases were found in the
lungs, liver, adrenal gland, and lymph nodes. These results
indicate that p53 and Rb cooperate in the prostate dur-
ing tumor progression and metastasis. PBCre4Rbflo xp53flo x
is similar to TRAMP in its aggressiveness, which makes
sense because the large T antigen has deleterious eﬀects
on both p53 and Rb. A basal phenotype was lost in
this model, but luminal markers and AR were expressed.
Neuroendocrine diﬀerentiation was also detected, especially
in metastatic lesions and after castration resistance occurred.
This histopathology is similar to what is seen in humans, and
diﬀerent from TRAMP because that model did not display
adenocarcinoma. Therefore, PBCre4Rbflo xp53flo xrepresentsa
valuable model for studying multiple stages of PCa but falls
short in terms of skeletal metastasis.
The Pten gene is one of the most studied genes
in PCa, and it was knocked out conditionally in mice
(PBCrePtenflox and PBCre4Ptenflox)[ 178]. These models
again point to the importance of Pten in the prostate,
and it was shown that the level of Pten knockdown
dictates the progression of PCa. Loss of heterozygosity of
Pten led to a shortened latency of PIN formation. The
conditional inactivation of Pten had complete penetrance,
and the prostate tumors were invasive and diﬀuse. Another
article was published at the same time that showed that
PBCre4Ptenfloxmicedevelopedmetastasisinthelymphnodes
and lung [179]. Notably, this was the ﬁrst mouse model in
which deletion of an endogenous gene induced metastatic
PCa. Castration resistance was detected, meaning that this
model represents one of the most accurate models of PCa
yet created, especially because Pten is frequently lost in
human PCa [194]. Although tumors in these mice do
not appear to metastasize to the skeleton, PBCre4Ptenflo x
is a useful model for the study and characterization of
PCa.
The canonical Wnt/β-catenin signaling pathway may
play an important role in PCa development. To investigate
the interaction of Wnt signaling in the prostate, a model
was generated to knock out the adenomatous polyposis
coli (APC) gene, which is a negative regulator of the
Wnt/β-catenin pathway [183]. By knocking out APC, the
Wnt pathway is constitutively active. PBCre4Apcflo x mice
developed PIN followed by locally invasive adenocarcinoma,
butdidnotdisplaydistantmetastasis.Uponcastrationbefore
tumorigenesis, carcinoma did not develop, but castration
after tumorigenesis resulted in retention of adenocarcinoma.
This indicates that these tumors are dependent on androgens
fortumorinitiationbutarecastrationresistantduringtumor
maintenance and progression. Similar results were seen in
the PBCre4Catnblox(ex3) mouse model, in which β-catenin
was overexpressed in its constitutively active form [185].
Due to the accumulating evidence that the Wnt/β-catenin
pathway is upregulated in PCa, this model proves to be
valuable.
MMTV-Cre. The mouse mammary tumor virus (MMTV)
has also been used to induce Cre expression. This is one
of the weaker constructs used to express Cre in conditional
models, due to its expression in many tissues including
prostate, mammary, skin, salivary gland, and seminal vesi-
cles. Therefore, any ﬂoxed region that is present in those
tissues during Cre recombination will be excised and could
develop a unique phenotype that aﬀects PCa development.
In one model (MMTVCreCatnblox(ex3)),MMTV-Crewasused
to remove exon 3 (which stabilizes the β-catenin protein)
from the β-catenin (Catnb) gene, thereby activating the
Wnt signaling pathway [188]. As expected, this model
displayed phenotypes in various tissues, including skin and
mammary. In the prostate, stabilization of β-catenin caused
hyperproliferation and loss of diﬀerentiation, resulting in
hyperplasia and metaplasia but not carcinoma. Another
model (MMTVCrePtenflo x) knocked out Pten in the prostate.
Cre-mediated recombination was also detected in several
other tissues due to the range of MMTV expression [189].
The prostates of these mice displayed increased proliferation
and HGPIN but did not progress to carcinoma or castration
resistance. It is diﬃcult to make salient conclusions about
thesemodelsduetothemultipleoﬀ-targeteﬀects.Therefore,
these models are not as valuable as those that are prostate
speciﬁc.Prostate Cancer 15
FSP1-Cre. The FSP1CreTGFβflox model places Cre expres-
sion under the control of the ﬁbroblast-speciﬁc protein 1
(FSP1) gene, which is exclusively expressed in ﬁbroblasts
after day 8.5 of embryonic development [190]. The inac-
tivated gene in this model is transforming growth factor
β (TGFβ), which is an important signaling molecule in
epithelial and mesenchymal interactions and may play a
role in neoplastic transformation of epithelial cells. Cre
recombination occurred in many other tissues because
ﬁbroblasts are present throughout the body. PIN was seen
in the prostates of these mice, while many other tissues
were histologically normal. This indicates that TGFβ may
play a tumor suppressive role via ﬁbroblast secretion in the
prostate. This model may be important in elucidating a role
for TGFβ in tissue diﬀerentiation, but it is not speciﬁc to the
prostate.
Nkx3.1-CreERT2. A recently described addition to the inven-
tory of prostate-speciﬁc Cre-expressing strains is the Nkx3.1-
Cre mouse that has thus far been used in one published
conditional model (Nkx3.1CreERT2Ptenflo x)[ 16]. The home-
obox protein Nkx3.1 has been shown to be expressed on
a rare population of luminal epithelial stem cells called
castration resistant Nkx3.1-expressing cells (CARNs) [16].
The Cre used in this model was fused to an ERT (tamoxifen-
inducible estrogen receptor) vector so that Cre is only active
upon tamoxifen treatment. Therefore, Cre activity can be
controlled so that the ﬂoxed region can be excised at speciﬁc
time points. It is important to note that tamoxifen treatment
could have phenotypic eﬀects on the prostate (such as
lowering testosterone levels [195]); therefore, experiments
must be thoroughly controlled. An additional stipulation is
that insertion of Cre results in one null allele for Nkx3.1,
making its expression heterozygous. This is important
because Nkx3.1 is haploinsuﬃcient: the loss of one Nkx3.1
allele results in mild PIN, and this could contribute to
any phenotype seen in these conditional knockouts. The
Nkx3.1-CreERT2 mouse was crossed to the Pten-ﬂox mouse
to knock out Pten activity in the prostate. This resulted in
rapid formation of hyperproliferative PIN and microinvasive
carcinoma, indicating that CARNs can act as a cell of origin
for prostate cancer, which has widespread implications for
PCa research as a whole. This model has clinical relevance
because if a castration resistant luminal stem cell is a cell
of origin for PCa, then it is possible that the castration
resistance seen in aggressive PCa is a result of transformation
of this cell type [16] .T h i sc o u l dl e a dt ot a r g e t e dt h e r a p y
for castration resistant PCa. The use of Nkx3.1CreERT2 to
inactivate other genes will be of great interest in future
models.
Summary. The conditional models we have discussed have
mostly knocked out the same genes that were knocked out
using the whole-body strategy. There are several advantages
of the conditional models over the traditional models. The
genetic event in the conditional models is localized to the
prostate, thereby allowing a more focused study of the genes’
roles. The conditional model allows for the study of genes
whose loss results in embryonic lethality, such as Rb or p53,
because those genes are still being expressed in every other
tissue. Conditional models are more accurate in terms of
mimicking the genetic events in a majority of cancer patients
in that a small portion of the body (even speciﬁc cell types)
display the genetic event, as opposed to the entire organism.
Finally, conditional models can be temporally controlled, for
instance through tamoxifen-inducible systems. The prostate
phenotypes seen in the conditional models are often more
severe than those seen in the traditional models. Consider
the Pten knockouts in particular; the traditional Pten models
resulted in PIN, but the conditional models resulted in
adenocarcinoma and metastasis (Tables 3 and 4), which may
beamoreaccuraterepresentationofwhathappensinhuman
patients. These disparate results indicate that there is still
more to learn about the tumorigenic properties of these
genes in the prostate.
3.2.6. Current and Future Models. No current mouse model
fully recapitulates all features of PCa. Xenograft studies
can swiftly add insight into molecular mechanisms and
microenvironment factors important in PCa. Years of mouse
modeling have also shown that mice can be predisposed to
cancer following correct manipulation of the germline. The
development of the Cre-loxP system has opened doors to
the potential generation of numerous PCa mouse models;
its ﬂexibility and utility will allow for swift development
of newer and more accurate models. A common strategy
for developing new models is to determine commonly
deregulatedgenesinhumanPCa(viamicroarrayanalysis,for
instance)andtheninduceoverexpressionordeletionofthose
genes in mice. There are several articles that discuss the var-
ious genetic abnormalities—including mutations, insertions
and deletions, and chromosomal translocations—that exist
in PCa [2, 196–200]. Theoretically, any of these genes can be
expressed or deleted to determine their physiological role in
tumorigenesis in the mouse. There are still many untested
genes.
An important point to make about GEMMs models
is that the mutation, excision, or overexpression of the
gene in question occurs throughout the entire body (in
the transgenic or whole knockouts) or entire tissue (in the
conditional models), and these genetic changes are present
from early development or birth. This does not compare
well to the situation in humans, in which mutations often
occur at random, possibly in a single cell, resulting in focal
disease development. It would be shortsighted to limit the
scope of the animal model to the types of models described
in this paper. We can expect newer, more sophisticated,
and more biologically diverse models in the future, which
will ideally address the challenging issues of the cell of
origin for PCa, new targets for castration resistant PCa, and
the molecular mechanisms and crosstalk causing skeletal
metastasis. A relatively unexplored area of PCa research in
mouse modeling is the role of the immune system, such
as inﬂammation or regulatory T cells, on PCa initiation,
progression, and metastasis. It is becoming more widely
accepted that the immune microenvironment, not only the
deregulation of genetic pathways, is important in PCa. While
a wealth of knowledge has been gained thus far from mouse16 Prostate Cancer
models,thereisaneedtocometoacommongroundonwhat
is agreed upon in the ﬁeld and what remains to be discovered
[49].
4. Conclusions
Ultimately, the goal of developing accurate experimental
models in the mouse is to study the eﬀects of drugs
for treating human disease. Especially imperative in PCa
research is the search for preventative measures or therapies
for castration resistant disease and skeletal metastases. Mod-
els that accurately recapitulate human disease can also be
used to determine the importance of various environmental
inﬂuences such as vitamin D, diet, and other factors; some
of these studies have already been done with several of the
models we have discussed [201, 202]. The development of
mouse models has brought us ever closer to ﬁnding better
therapies for PCa.
Mouse models are suited to answering important ques-
tions in PCa research, such as the cell of origin for PCa,
molecular diﬀerences between indolent and aggressive PCa,
and factors that are necessary for metastasis of PCa tumor
cells to the skeleton. However, mice may not display all
the heterogeneity seen in humans or represent every stage
of human PCa, and their tumors may not metastasize to
the same tissues as in humans. All of these possibilities
must be taken into account when developing a mouse
model, and the best way to accurately represent all of these
aspects is to target the correct genes in the correct cell(s)
of origin of PCa. Mouse models as a whole represent rich
heterogeneityofgeneticexpression.Onemodelwillprobably
not fully encompass all of the various stages and aspects
of human disease. Instead, a variety of models may be
needed to study diﬀerent aspects of PCa, and xenograft
models may likely play a critical role, especially in metastatic
studies. In order to expand the present collection of models,
we must know the genetic variations and gene expression
patterns so that we can accurately categorize PCa. The
pairing of genetic characterization of human PCa and the
improvement of mouse models will be the most eﬀective way
of advancing overall knowledge and available treatments for
this widespread disease.
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